SIBN Share Price | SI-BONE, Inc. Stock Analysis & Recommendation

Q: What does SI-BONE, Inc. do?

Overview: SI-BONE, Inc. is focused on the development of medical devices within the Pharmaceuticals & Biotechnology industry, specifically for minimally invasive surgical solutions for sacroiliac joint disorders.Financial Snapshot: Net Sales: 47 Million (Quarterly Results - Mar 2025) Net Profit: -7 Million (Quarterly Results - Mar 2025) Market cap: USD 730.84 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -0.64 Return on Equity: -15.87% Price to Book: 4.37Contact Details: Address: 471 El Camino Real Ste 101, SANTA CLARA CA: 95050-4482 Tel: 1 408 2070700 Fax: 1 408 5578312 Website: https://si-bone.com/

Q: Should I buy, sell or hold SI-BONE, Inc.?

Based on the current situation with SI-BONE, Inc., it would be advisable to hold your position in the stock. The company has shown positive results for the last nine consecutive quarters, which is a good sign. However, the long-term growth outlook appears weak, with an operating profit growth rate of only 2.66% over the past five years.Additionally, the company is facing challenges with negative EBITDA and a high net profit loss of USD -11.04 million. While the stock has generated a return of 0% over the past year, profits have increased by 38.4%, indicating some potential for improvement. It's also worth noting that institutional investors hold 100% of the stock, which suggests a level of confidence from those with more resources to analyze the company's fundamentals. Given these factors, holding your investment seems to be the most prudent course of action for now.

Q: Is SI-BONE, Inc. technically bullish or bearish?

As of 3 October 2025, the technical trend has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a bearish MACD on the weekly timeframe and a bearish RSI on the monthly timeframe. The daily moving averages also indicate a bearish trend. While the monthly KST shows bullishness, the overall indicators suggest weakness. There is no available return data to compare SI-BONE, Inc. against the S&P 500.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

662.22 k

Shareholding (Dec 2025)

FII

11.45%

Held by 87 FIIs

DII

48.67%

Held by 39 DIIs

Promoter

5.97%

How big is SI-BONE, Inc.?

22-Jun-2025

As of Jun 18, SI-BONE, Inc. has a market capitalization of 730.84 million, with net sales of 176.60 million and a net profit of -26.56 million over the last four quarters. Shareholder's funds are 166.96 million, and total assets are 230.44 million.

View full answer

What does SI-BONE, Inc. do?

22-Jun-2025

SI-BONE, Inc. develops minimally invasive surgical devices for sacroiliac joint disorders, with a market cap of approximately $730.84 million and quarterly net sales of $47 million, but currently reports a net loss of $7 million.

View full answer

Should I buy, sell or hold SI-BONE, Inc.?

22-Jun-2025

Who are in the management team of SI-BONE, Inc.?

22-Jun-2025

As of March 2022, the management team of SI-BONE, Inc. includes Mr. Jeffrey Dunn as Chairman, President, and CEO, with Mr. Timothy Davis as Lead Independent Director and independent directors Mr. Mark Foley, Dr. John Freund, Ms. Jeryl Hilleman, and Mr. Gregory Hinckley.

View full answer

Is SI-BONE, Inc. technically bullish or bearish?

07-Oct-2025

As of October 3, 2025, the trend for SI-BONE, Inc. has shifted to mildly bearish, indicated by a bearish MACD and RSI, despite some bullishness in the monthly KST.

View full answer

Compare SI-BONE, Inc. with Similar Stocks

MiMedx Group, Inc.Avanos Medical, Inc.Paragon 28, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Poor long term growth as Operating profit has grown by an annual rate 5.99% of over the last 5 years

The company has declared Positive results for the last 9 consecutive quarters

Risky -

High Institutional Holdings at 100%

Consistent Underperformance against the benchmark over the last 3 years

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 568 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.63

Return on Equity

-12.64%

Price to Book

3.30

Revenue and Profits:

Net Sales:

56 Million

(Quarterly Results - Dec 2025)

Net Profit:

-2 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-33.73%

6 Months

-14.77%

1 Year

-12.75%

2 Years

-19.76%

3 Years

-36.1%

4 Years

-35.94%

5 Years

-57.73%

SI-BONE, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

22.20%

EBIT Growth (5y)

5.99%

EBIT to Interest (avg)

-13.19

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.64

Sales to Capital Employed (avg)

0.76

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

3.30

EV to EBIT

-18.11

EV to EBITDA

-22.95

EV to Capital Employed

7.28

EV to Sales

2.37

PEG Ratio

Dividend Yield

ROCE (Latest)

-40.22%

ROE (Latest)

-12.64%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Bullish

Dow Theory

Mildly Bearish

OBV

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 57 Schemes (33.9%)

Foreign Institutions

Held by 87 Foreign Institutions (11.45%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 14.90% vs 25.96% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 64.44% vs 59.09% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "56.30",
          "val2": "49.00",
          "chgp": "14.90%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.80",
          "val2": "-4.30",
          "chgp": "81.40%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.60",
          "val2": "0.80",
          "chgp": "-25.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1.60",
          "val2": "-4.50",
          "chgp": "64.44%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-43.70%",
          "val2": "-112.10%",
          "chgp": "6.84%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 20.16% vs 20.37% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 38.83% vs 28.64% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "200.90",
          "val2": "167.20",
          "chgp": "20.16%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-16.60",
          "val2": "-30.90",
          "chgp": "46.28%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "2.60",
          "val2": "3.40",
          "chgp": "-23.53%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-18.90",
          "val2": "-30.90",
          "chgp": "38.83%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-111.10%",
          "val2": "-210.80%",
          "chgp": "9.97%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY

Dec'25

Dec'24

Change(%)

Net Sales

56.30

49.00

14.90%

Operating Profit (PBDIT) excl Other Income

-0.80

-4.30

81.40%

Interest

0.60

0.80

-25.00%

Exceptional Items

0.00

Consolidate Net Profit

-1.60

-4.50

64.44%

Operating Profit Margin (Excl OI)

-43.70%

-112.10%

6.84%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2025 is 14.90% vs 25.96% in Dec 2024

Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is 64.44% vs 59.09% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

200.90

167.20

20.16%

Operating Profit (PBDIT) excl Other Income

-16.60

-30.90

46.28%

Interest

2.60

3.40

-23.53%

Exceptional Items

0.00

Consolidate Net Profit

-18.90

-30.90

38.83%

Operating Profit Margin (Excl OI)

-111.10%

-210.80%

9.97%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 20.16% vs 20.37% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 38.83% vs 28.64% in Dec 2024

All Annual Results

Company CV

About SI-BONE, Inc.

SI-BONE, Inc.

Pharmaceuticals & Biotechnology

SI-BONE, Inc. is focused on development of medical devices. The Company is engaged in the development, manufacture and commercialization of minimally invasive surgical devices for the treatment of patients with low back symptoms related to certain sacroiliac (SI) joint disorders. The Company offers iFuse Implant System, which provides a minimally invasive surgical solution to fuse the SI joint using patented triangular titanium implants that create an interference fit within the ilium and sacrum. The triangular implant shape, combined with the press fit insertion, is designed to provide fixation by minimizing rotational motion. The implants has a porous surface that provide an environment for bone ongrowth and ingrowth, facilitating long-term fusion of the joint. The iFuse Implant System is intended for sacroiliac fusion for conditions, including sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis.

Company Coordinates

Company Details

471 El Camino Real Ste 101 , SANTA CLARA CA : 95050-4482

Tel: 1 408 2070700

https://si-bone.com/

Registrar Details